PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT VAXART, INC.Vaxart, Inc. • March 20th, 2019 • Biological products, (no disgnostic substances) • New York
THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on March 19, 2024 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Vaxart, Inc., a Delaware corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain Engagement Agreement, by and between the Company and H.C. Wainwright & Co., LLC dated as of January 25, 2019 (the “Engagement Agreement”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 20th, 2019 • Vaxart, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 19, 2019, between Vaxart, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
STRICTLY CONFIDENTIAL Vaxart, Inc.Letter Agreement • March 20th, 2019 • Vaxart, Inc. • Biological products, (no disgnostic substances) • New York
